ABOG Gynecologic Oncology study plan

Construct a one-page decision table for cervical cancer screening that compares primary HPV testing, co-testing, and cytology alone by age band and by prior abnormal result history.

Map the risk-based management thresholds that separate colposcopy referral, expedited treatment, and surveillance so you can justify each branch without notes.

Trace the diagnostic pathway for postmenopausal bleeding from transvaginal ultrasound through endometrial sampling, and state the sensitivity and limitations of each step.

Differentiate the hereditary cancer syndromes relevant to gynecologic practice (BRCA1/BRCA2, Lynch spectrum, Li-Fraumeni, Cowden) and match each to its surveillance and risk-reducing surgery recommendations.

Explain the evidence base and known harms of ovarian cancer screening in average-risk women well enough to counsel a patient in plain language.

Outline the staging and cytoreductive operations for ovarian, endometrial, cervical, and vulvar cancer, listing the anatomic landmarks and the extent of resection each requires.

Compare sentinel lymph node mapping against systematic lymphadenectomy for endometrial and cervical cancer, including the injection techniques, detection rates, and situations where each is preferred.

Specify the eligibility criteria and oncologic caveats for fertility-sparing surgery in early cervical, endometrial, and ovarian disease.

Classify radical hysterectomy by the modern parametrectomy-based system and match each class to its nerve, ureteral, and bladder outcomes.

Assemble the perioperative enhanced-recovery elements and the three most common postoperative complications that change adjuvant planning.

Build a regimen map that links each major gynecologic cancer setting (frontline, platinum-sensitive recurrence, platinum-resistant recurrence, maintenance) to its standard backbone and cycle length.

Group the cytotoxic agents used in gynecologic oncology by mechanism and assign each its dose-limiting toxicity and the organ system that requires dose modification.

State the indications and trial rationale for PARP inhibitor maintenance, including homologous recombination status and prior platinum response.

Distinguish the checkpoint-inhibitor indications in cervical and endometrial cancer by biomarker selection and line of therapy.

Draft a management sequence for four chemotherapy emergencies: febrile neutropenia, hypersensitivity infusion reaction, extravasation injury, and grade 3 peripheral neuropathy.

Contrast external beam radiotherapy with brachytherapy in terms of dose distribution, fractionation, and the clinical situations that demand each.

Reproduce the target doses and fractionation schemes used for definitive cervical, adjuvant endometrial, and vulvar radiotherapy.

Explain the radiobiologic principles - the alpha/beta ratio, repair, repopulation, redistribution, and reoxygenation - and predict how they drive altered fractionation.

List the normal-tissue dose constraints for bladder, rectum, bowel, and bone marrow and identify which violation triggers replanning.

Justify concurrent chemoradiation versus radiotherapy alone for each disease site using the level of evidence that supports it.

Classify each major gynecologic tumor by histologic subtype, grade, and the immunohistochemical panel that resolves the differential.

Explain the molecular drivers - TP53, PTEN/PI3K, ARID1A, mismatch repair deficiency, HER2, and homologous recombination deficiency - and connect each to a therapy decision made earlier in the plan.

Describe the mechanisms of resistance to platinum and to PARP inhibition and the tumor biology that underlies them.

Interpret common pathology report elements, including margin status, lymphovascular space invasion, and peritoneal cytology, for their prognostic weight.

Interpret hazard ratios, confidence intervals, number needed to treat, and Kaplan-Meier curves from gynecologic oncology trials without relying on the abstract conclusion.

Distinguish phase I, II, and III designs and identify the specific biases that threaten each, including lead-time, selection, and attrition bias.

Summarize the design and practice-changing result of landmark trials in cervical, endometrial, and ovarian cancer using only the primary endpoint and the magnitude of benefit.

Build a symptom-management plan for malignant bowel obstruction, lymphedema, and cancer-related pain that includes opioid titration and adverse-effect prophylaxis.

Explain the goals-of-care conversation framework and the ethical and communication elements that support it.

Re-audit every missed item from weeks 1 through 6 and rewrite each as a testable fact with its supporting rationale.

Rehearse 60 timed mixed-domain questions to build pacing and to expose residual weak links across all six domains.

Construct complete management algorithms for four high-yield scenarios: newly diagnosed advanced ovarian cancer, locally advanced cervical cancer, grade 3 endometrioid endometrial cancer, and recurrent platinum-resistant disease.

Verbalize the surgical, systemic, and radiation options for each of those scenarios and defend the sequencing aloud in under five minutes.

Complete two full-length 150-question simulated exams under strict timing and record the domain-level score breakdown for each.

Diagnose the top three remaining deficits by domain and by error type - knowledge gap versus reasoning error versus misread stem.

Re-teach each of those deficits in writing from memory, then verify against a primary source.

Consolidate the highest-yield tables, algorithms, and toxicities into a single final-review document for the last 48 hours.